Amgen acquires rights from Boehringer Ingelheim for BI 836908 (AMG 420)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AMGEN and Boehringer Ingelheim said Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in phase I studies. Under the agreement, Amgen will work with Boehringer...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login